Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
7.23.2015
England NHS cancer drug fund to be handed over to NICE?
Dear All,
Some interesting developments on the Cancer Drug Fund have been announced today.
No comments:
Post a Comment